Maspin expression in gastrointestinal stromal tumors
dc.contributor.buuauthor | Adım, Şaduman Balaban | |
dc.contributor.buuauthor | Filiz, Gülaydan | |
dc.contributor.buuauthor | Kanat, Özkan | |
dc.contributor.buuauthor | Yerci, Ömer | |
dc.contributor.buuauthor | Özgüç, Halil Bülent | |
dc.contributor.buuauthor | Aytaç, Berna | |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Patoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı. | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.researcherid | AAH-9746-2021 | tr_TR |
dc.contributor.scopusid | 15730076300 | tr_TR |
dc.contributor.scopusid | 6602693514 | tr_TR |
dc.contributor.scopusid | 55881548500 | tr_TR |
dc.contributor.scopusid | 6603810549 | tr_TR |
dc.contributor.scopusid | 6603867989 | tr_TR |
dc.contributor.scopusid | 56527372000 | tr_TR |
dc.date.accessioned | 2022-06-28T11:31:41Z | |
dc.date.available | 2022-06-28T11:31:41Z | |
dc.date.issued | 2010-03-26 | |
dc.description.abstract | Background: To investigate the role of maspin expression in the progression of gastrointestinal stromal tumors, and its value as a prognostic indicator. Methods: In the study 54 patients with GIST diagnosis were included in Uludag University of Faculty of Medicine, Department of Pathology between 1997-2007. The expression of maspin in 54 cases of gastrointestinal stromal tumor was detected by immunohistochemistry and compared with the clinicopathologic tumor parameters. Results: The positive expression rates for maspin in the GISTs were 66,6% (36 of 54 cases). Maspin overexpression was detected in 9 of 29 high risk tumors (31%) and was significantly higher in very low/low (78.6%) and intermediate-risk tumors (63.6%) than high-risk tumors. Conclusions: Maspin expression might be an important factor in tumor progression and patient prognosis in GIST. In the future, larger series may be studied to examine the prognostic significance of maspin in GISTs and, of course, maspin expression may be studied in different mesenchymal tumors. | en_US |
dc.identifier.citation | Adım, Ş. B. vd. (2010). "Maspin expression in gastrointestinal stromal tumors". World Journal of Surgical Oncology, 8. | en_US |
dc.identifier.issn | 1477-7819 | |
dc.identifier.pubmed | 20346150 | tr_TR |
dc.identifier.scopus | 2-s2.0-77952309178 | tr_TR |
dc.identifier.uri | https://doi.org/10.1186/1477-7819-8-22 | |
dc.identifier.uri | https://wjso.biomedcentral.com/articles/10.1186/1477-7819-8-22 | |
dc.identifier.uri | http://hdl.handle.net/11452/27440 | |
dc.identifier.volume | 8 | tr_TR |
dc.identifier.wos | 000276760000001 | tr_TR |
dc.indexed.pubmed | PubMed | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.wos | SCIE | en_US |
dc.language.iso | en | en_US |
dc.publisher | BMC | en_US |
dc.relation.journal | World Journal of Surgical Oncology | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Paradoxical expression | en_US |
dc.subject | P53 expression | en_US |
dc.subject | Gene | en_US |
dc.subject | Carcinoma | en_US |
dc.subject | Cancer | en_US |
dc.subject | Angiogenesis | en_US |
dc.subject | Progression | en_US |
dc.subject | Mammary | en_US |
dc.subject | Serpin | en_US |
dc.subject | Cells | en_US |
dc.subject | Oncology | en_US |
dc.subject | Surgery | en_US |
dc.subject.emtree | Maspin | en_US |
dc.subject.emtree | Serine proteinase inhibitor | en_US |
dc.subject.emtree | SERPIN B5 | en_US |
dc.subject.emtree | SERPIN-B5 | en_US |
dc.subject.emtree | Tumor marker | en_US |
dc.subject.emtree | Acute pancreatitis | en_US |
dc.subject.emtree | Adolescent | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Cancer diagnosis | en_US |
dc.subject.emtree | Cancer growth | en_US |
dc.subject.emtree | Cancer localization | en_US |
dc.subject.emtree | Cancer risk | en_US |
dc.subject.emtree | Controlled study | en_US |
dc.subject.emtree | Female | en_US |
dc.subject.emtree | Follow up | en_US |
dc.subject.emtree | Gastrointestinal stromal tumor | en_US |
dc.subject.emtree | High risk patient | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human cell | en_US |
dc.subject.emtree | Immunohistochemistry | en_US |
dc.subject.emtree | Major clinical study | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Metastasis | en_US |
dc.subject.emtree | Overall survival | en_US |
dc.subject.emtree | Prognosis | en_US |
dc.subject.emtree | Protein expression | en_US |
dc.subject.emtree | Survival rate | en_US |
dc.subject.emtree | Tumor growth | en_US |
dc.subject.emtree | Cancer staging | en_US |
dc.subject.emtree | Disease course | en_US |
dc.subject.emtree | Enzyme immunoassay | en_US |
dc.subject.emtree | Gastrointestinal stromal tumor | en_US |
dc.subject.emtree | Metabolism | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Pathology | en_US |
dc.subject.emtree | Risk factor | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Disease progression | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal stromal tumors | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Immunoenzyme techniques | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Neoplasm staging | en_US |
dc.subject.mesh | Prognosis | en_US |
dc.subject.mesh | Risk factors | en_US |
dc.subject.mesh | Serpins | en_US |
dc.subject.mesh | Survival rate | en_US |
dc.subject.mesh | Tumor markers, biological | en_US |
dc.subject.mesh | Young adult | en_US |
dc.subject.scopus | SERPIN-b5; Serine Proteinase Inhibitors; Serpins | en_US |
dc.subject.wos | Oncology | en_US |
dc.subject.wos | Surgery | en_US |
dc.title | Maspin expression in gastrointestinal stromal tumors | en_US |
dc.type | Article | |
dc.wos.quartile | Q4 (Oncology) | en_US |
dc.wos.quartile | Q3 (Surgery) | en_US |